Together, these diverse actions—spanning metabolic, inflammatory, oxidative, mitochondrial, and vascular domains—underscore the therapeutic potential of GLP-1RAs in counteracting sarcopenia in CKD, even in the absence of confirmed GLP-1R expression in human muscle cells. This evidence concerns the gene GLP1R and chronic kidney disease.